Aaron Seth Rosenberg1, Scott Bainbridge2, Roma Pahwa2, Ishwarlal Jialal3. 1. Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, Sacramento, CA, United States. 2. Department of Pathology and Laboratory Medicine, UC Davis Medical Center, Sacramento, CA, United States. 3. Department of Pathology and Laboratory Medicine, UC Davis Medical Center, Sacramento, CA, United States. Electronic address: kjialal@gmail.com.
Abstract
OBJECTIVES: Recently monoclonal antibody therapy has been introduced in the treatment of multiple Myeloma (MM). One such efficacious therapy is the anti-CD38 monoclonal antibody, daratumumab (Dara). Since it is an Ig-G-kappa it can interfere with both the serum protein electrophoresis and immunofixation electrophoresis (IFE). The free light chain (FLC) assay is also useful in the diagnosis and therapeutic monitoring of MM. Hence we tested the effect of Dara on the FLC assay. METHODS: 30 serum samples from patients with known IgG-kappa (n=20) and non-IgG-kappa M -proteins (n=10) were spiked with Dara at a final concentration of 1.0mg/mL and the FLC performed on samples. On a further 20 samples we performed IFE to determine the migration of Dara. RESULTS: On IFE, Dara migrated in the same area of the gamma zone. In the 30 samples in which we assayed FLC there was no significant differences in levels of kappa, lambda and the ratio of kappa to lambda between untreated and Dara-spiked samples. CONCLUSION: Whilst Dara can interfere with the IFE to determine clinical responses the FLC assay can be useful in patients who have abnormal FLC ratios prior to Dara therapy to determine responses especially in IgG-kappa Myeloma.
OBJECTIVES: Recently monoclonal antibody therapy has been introduced in the treatment of multiple Myeloma (MM). One such efficacious therapy is the anti-CD38 monoclonal antibody, daratumumab (Dara). Since it is an Ig-G-kappa it can interfere with both the serum protein electrophoresis and immunofixation electrophoresis (IFE). The free light chain (FLC) assay is also useful in the diagnosis and therapeutic monitoring of MM. Hence we tested the effect of Dara on the FLC assay. METHODS: 30 serum samples from patients with known IgG-kappa (n=20) and non-IgG-kappa M -proteins (n=10) were spiked with Dara at a final concentration of 1.0mg/mL and the FLC performed on samples. On a further 20 samples we performed IFE to determine the migration of Dara. RESULTS: On IFE, Dara migrated in the same area of the gamma zone. In the 30 samples in which we assayed FLC there was no significant differences in levels of kappa, lambda and the ratio of kappa to lambda between untreated and Dara-spiked samples. CONCLUSION: Whilst Dara can interfere with the IFE to determine clinical responses the FLC assay can be useful in patients who have abnormal FLC ratios prior to Dara therapy to determine responses especially in IgG-kappa Myeloma.
Authors: Luzalba Sanoja-Flores; Juan Flores-Montero; Noemi Puig; Teresa Contreras-Sanfeliciano; Roberia Pontes; Alba Corral-Mateos; Omar García-Sánchez; María Díez-Campelo; Roberto José Pessoa de Magalhães; Luis García-Martín; José María Alonso-Alonso; Aranzazú García-Mateo; Carlos Aguilar-Franco; Jorge Labrador; Abelardo Barez-García; Angelo Maiolino; Bruno Paiva; Jesús San Miguel; Elaine Sobral da Costa; Marcos González; María Victoria Mateos; Brian Durie; Jacques J M van Dongen; Alberto Orfao Journal: Blood Date: 2019-12-12 Impact factor: 22.113
Authors: Carlo O Martins; Sarah Huet; San S Yi; Maria S Ritorto; Ola Landgren; Ahmet Dogan; Jessica R Chapman Journal: J Mol Diagn Date: 2020-04-14 Impact factor: 5.568